The Korea Herald reports that Celltrion is on track to file applications for U.S. FDA approval for its rituximab and trastuzumab biosimilars by June. According to the article (and as previously reported), once approved, the drugs will be sold through Celltrion’s U.S. commercial partner, Teva Pharmaceutical Industries Ltd.